Jazz Pharmaceuticals announced that the European Commission has granted marketing authorization for Enrylaze for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. Enrylaze, approved as Rylaze in the United States and Canada, is a new Erwinia-derived asparaginase developed using a next-generation recombinant technology with a safety profile consistent with that of other asparaginase preparations.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on JAZZ:
- Jazz Pharmaceuticals promotes CFO Renee Gala to COO
- Jazz Pharmaceuticals: Oxybate improved measures of sleep in study
- Jazz Pharmaceuticals added to ‘US 1 list’ at BofA
- Jazz Pharmaceuticals price target lowered to $180 from $210 at Cantor Fitzgerald
- Jazz Pharmaceuticals price target raised to $217 from $204 at BofA